IMR Press / FBL / Volume 27 / Issue 11 / DOI: 10.31083/j.fbl2711304
Open Access Review
N6-Methyladenosine-Modification-Related Ophthalmic Diseases and Potential Therapeutic Strategies
Show Less
1 Department of Ophthalmology, The Second Clinical Medical College of Jinan University, 518020 Shenzhen, Guangdong, China
2 Department of Ophthalmology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University), 518020 Shenzhen, Guangdong, China
*Correspondence: (Yali Gao)
Academic Editor: Alika K. Maunakea
Front. Biosci. (Landmark Ed) 2022, 27(11), 304;
Submitted: 18 July 2022 | Revised: 11 October 2022 | Accepted: 12 October 2022 | Published: 11 November 2022
Copyright: © 2022 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

The N6-methyladenosine (m6A) is the most abundant internal modification in advanced eukaryotic mRNAs, and it plays an important role in mRNA metabolism and diverse biological processes. Moreover, m6A modification is dynamically reversible and may reshape gene expression patterns after demethylation induced by drug interventions, which may reverse the occurrence and progression of certain diseases. Although the role of changes in DNA methylation in ophthalmic diseases has been well described, the regulatory role of the m6A modification in ophthalmic diseases is still a new field of study. This paper aims to systematically summarize the latest research progress about m6a-modification-related ophthalmic diseases and potential therapeutic strategies. All English literature relevant to our research was searched in PubMed and CNKI databases, using appropriate keywords. Our study reviews the regulatory role of m6A in ophthalmic diseases. It covers almost all of the reported m6A-related ophthalmic diseases and proposes potential treatment strategies for each disease. This review will provide direction for further research on m6A in ophthalmic diseases and help in the treatment of ophthalmic diseases in the future.

m6A modification
m6A enzymes
ophthalmic diseases
potential therapeutic strategies
2019A1515010412/Natural Science Foundation of Guangdong Province
81902751/National Natural Science Foundation of China
81971385/National Natural Science Foundation of China
SYKYPY201927/Researcher Cultivation Project of Shenzhen People's Hospital
Fig. 1.
Back to top